US Court Rules in Favor of AstraZeneca in Symbicort Patent Litigation
03 March 2021 - 6:49PM
Dow Jones News
By Cecilia Butini
AstraZeneca PLC said Wednesday that the U.S. District Court for
the Northern District of West Virginia has decided in its favor in
litigation regarding patents protecting its asthma medication
Symbicort.
Litigation was against Mylan Pharmaceuticals Inc. and Kindeva
Drug Delivery LP and was initiated with claims of infringement of
various U.S. patents covering Symbicort, the British pharmaceutical
giant said.
A third company, 3M Co., was initially part of the lawsuit but
later dismissed from the case, AstraZeneca said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 03, 2021 02:34 ET (07:34 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From May 2023 to May 2024
